Global Trigeminal Neuralgia Treatment Market Overview:
Trigeminal neuralgia is a sudden and severe facial pain. It is often termed as a sense of sharp shooting pain or that similar to having an electric shock in the jaws, teeth or gums. This usually occurs in short, impulsive attacks which can last for a few seconds to nearly around 2 minutes. These attacks stop just as suddenly they start. In most of the cases, trigeminal neuralgia upsets just one side of the face, with the pain typically felt in the lower part of the face. Very rarely it happens that the pain affects both sides of the face, while this does not usually occur at the same time. Trigeminal neuralgia is mainly caused due to the compression of the trigeminal nerve. This is the nerve that is present inside the skull which transmits all the sensations regarding pain and touches from the face, mouth, and teeth to the brain. The compression of this nerve is generally caused by a close blood vessel that is pressing on the part of the nerve that is inside the skull. Trigeminal neuralgia is generally a long-term condition and the periods of retardation often get shorter over time. However, the treatments that are available do help most of the cases to some degree. An anticonvulsant medicine is known as carbamazepine, which is frequently used to treat epilepsy, is the ever first treatment that is usually recommended to treat trigeminal neuralgia. Carbamazepine can release the nerve pain by slowing down the electrical impulses in the nerves and further reducing the ability to transmit the pain messages. There are also some minor surgical procedures that can be used for the purpose of treating trigeminal neuralgia, but these procedures are normally only effective for a very few years. Otherwise, the specialist may further recommend having surgery so as to open the skull and remove any blood vessels which are compressing the trigeminal nerve. Some of the key players profiled in the study are Allergan Plc (Ireland), Biogen, Inc. (United States), Kineta Inc. (United States), Mayo Clinic (United States), Merz Pharma GmbH & Co. (Germany), Trigemina Inc. (United States), Mayfield Brain & Spine (United States), Abbott Laboratories (United States), Pfizer Inc. (United States) and GlaxoSmithKline Plc. (United Kingdom).
On the basis of geography, the market of Trigeminal Neuralgia Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Medicine Type, the sub-segment i.e. Anticonvulsant will boost the Trigeminal Neuralgia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Surgery Type, the sub-segment i.e. Rhizotomy will boost the Trigeminal Neuralgia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Men will boost the Trigeminal Neuralgia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- The Rising Cases of Problems Related to Nerves
- Advanced Diagnostic Technology and New Treatments
- A Rise in the Aging Population With Growing Healthcare Infrastructure
- Growing Trend of Extended Insurance Cover
- The Rising Government Initiatives Regarding Health of People and Emerging Economies
- The High cost Associated with Trigeminal Neuralgia Treatment
- Growing R&D and the Advent of Latest Technological in the Field of Healthcare
- Unawareness About the Treatments for Trigeminal Neuralgia
Major Market Developments:
On, January 13th, 2020, Biogen Inc. announced an agreement to acquire from Pfizer Inc., a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases. In particular, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimerís disease (AD) and Irregular Sleep-Wake Rhythm Disorder (ISWRD) in Parkinsonís disease (PD). The purchase will include an upfront payment of USD 75 million with up to USD 635 million in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens.
On, February 27th, 2020, Biogen Inc. and Sangamo Therapeutics, Inc., a genomic medicine company, had announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimerís disease, ST-502 for synucleinopathies including Parkinsonís disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets. The companies will leverage Sangamoís proprietary zinc finger protein (ZFP) technology delivered via adeno-associated virus (AAV) to modulate the expression of key genes involved in neurological diseases.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
Providers of Trigeminal Neuralgia Treatment, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others
Major Objectives Focused through this Study
To define, describe, and forecast the Global Trigeminal Neuralgia Treatment market on the basis of product [Medication and Surgery] , application [Hospitals, Clinics and Medical Research Centers], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Trigeminal Neuralgia Treatment market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Trigeminal Neuralgia Treatment industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Novartis (Switzerland) and Shire (United States).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Trigeminal Neuralgia Treatment market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.